Vera Therapeutics, Inc. (VERA) Research
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Market snapshot
- Symbol
- VERA
- Price
- $35.09
- Day change
- +0.23%
- Market cap
- $2.5B
- P/E ratio
- -6.80x
- 52-week range
- 19.066-56.05
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $80.33
Peer companies
Recent insider activity
- Morrison Scott W — A-Award (17084 shares) on 2026-05-21
- Cheng Andrew — A-Award (17084 shares) on 2026-05-21
- SEIDENBERG BETH C — A-Award (17084 shares) on 2026-05-21
- Oliger Christy J. — A-Award (17084 shares) on 2026-05-21
- Meyers James R — A-Award (17084 shares) on 2026-05-21
Open Vera Therapeutics, Inc. (VERA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.